Dhiren Patel
Vice President - Clinical Development Actinium Pharmaceuticals
Seminars
Wednesday 22nd July 2026
De-Risking First-in-Human PSMA Radioligand Therapy by Translating Terbium-161 Biology, Dosimetry, & Safety into Early-Phase Dose Decisions
2:00 pm
- Exploring whether dual beta–Auger emissions can control tumors effectively without surprising early side effects
- Finding safe and scalable dose levels that turn promising microdosimetry into confident first-in-human decisions
- Gathering early clinical signals to guide go/ no-go decisions before larger, resource-heavy trials
